School of Medicine, University of Kragujevac, 34000 Kragujevac, Serbia.
Department of Oncology and Hematology, Todua Clinic, 0112 Tbilisi, Georgia.
Curr Oncol. 2022 Oct 31;29(11):8316-8329. doi: 10.3390/curroncol29110656.
Consolidation systemic therapy (ST) given after concurrent radiotherapy (RT) and ST (RT-ST) is frequently practiced in locally advanced inoperable nonsmall cell lung cancer (NSCLC). Little is known, however, about the fate of patients achieving different responses after concurrent phases of the treatment.
we searched the English-language literature to identify full-length articles on phase II and Phase III clinical studies employing consolidation ST after initial concurrent RT-ST. We sought information about response evaluation after the concurrent phase and the outcome of these patient subgroups, the patterns of failure per response achieved after the concurrent phase as well as the outcome of these subgroups after the consolidation phase.
Eighty-seven articles have been initially identified, of which 20 studies were excluded for various reasons, leaving, therefore, a total of 67 studies for our analysis. Response evaluation after the concurrent phase was performed in 36 (54%) studies but in only 14 (21%) response data were provided, while in 34 (51%) studies patients underwent a consolidation phase regardless of the response. No study provided any outcome (survivals, patterns of failure) as per response achieved after the concurrent phase.
Information regarding the outcome of subgroups of patients achieving different responses after the concurrent phase and before the administration of the consolidation phase is still lacking. This may negatively affect the decision-making process as it remains unknown which patients may preferentially benefit from the consolidation of ST.
在同步放化疗（RT）后给予巩固全身治疗（ST）是局部晚期不可手术的非小细胞肺癌（NSCLC）的常用治疗方法。然而，对于在治疗同步阶段后获得不同反应的患者的命运，我们知之甚少。
我们检索了英文文献，以确定在初始同步 RT-ST 后采用巩固 ST 的 II 期和 III 期临床试验的全文文章。我们寻求关于同步阶段后反应评估以及这些患者亚组的结果的信息，以及在同步阶段后获得的这些反应亚组的失败模式以及巩固阶段后的这些亚组的结果。
最初确定了 87 篇文章，其中 20 篇因各种原因被排除在外，因此，共有 67 篇研究用于我们的分析。有 36 项（54%）研究进行了同步阶段后的反应评估，但仅有 14 项（21%）提供了反应数据，而在 34 项（51%）研究中，无论反应如何，患者都接受了巩固阶段的治疗。没有研究按照同步阶段后获得的反应提供任何结果（生存情况、失败模式）。
关于在同步阶段后获得不同反应的患者亚组在接受巩固 ST 治疗前的结果信息仍然缺乏。这可能会对决策过程产生负面影响，因为尚不清楚哪些患者可能会从巩固 ST 中优先获益。
